Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Spatiotemporal Profiling Defines the Epithelial and Mesenchymal Transition Window in Embryonic Lung Morphogenesis.

Journal of developmental biology·2026

Same author

Hospital Closures Increase Emergency Care Travel Time: Rural-Urban Disparities.

Inquiry : a journal of medical care organization, provision and financing·2026

Same author

Ciprofol-etomidate versus propofol-etomidate for gastrointestinal endoscopy: a randomized, double-blind controlled clinical trial.

Frontiers in medicine·2026

Same author

Inhibition of host N-myristoylation compromises the infectivity of SARS-CoV-2 due to Golgi-bypassing egress.

Nature communications·2026

Same author

Evaluation of a new droplet digital PCR for diagnosis of pulmonary tuberculosis and tuberculous pleurisy.

Frontiers in medicine·2026

Same author

Knowledge, Attitudes, and Practices Towards Atopic Dermatitis Among Parents of Children with Atopic Dermatitis: A Cross-Sectional Study.

Journal of asthma and allergy·2026

Search research articles

Related Experiment Video

Updated: Dec 21, 2025

Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies

Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies

Published on: August 29, 2017

Recent Progress toward Engineering HIV-1-Specific Neutralizing Monoclonal Antibodies.

Ming Sun¹, Yue Li², Huiwen Zheng¹

¹Institute of Medical Biology, Peking Union Medical College, Chinese Academy of Medical Sciences , Kunming , China.

Frontiers in Immunology

|October 18, 2016

Summary

Engineered antibodies offer a new approach to HIV-1 treatment and prevention. Research focuses on improving broadly neutralizing antibodies (bNAbs) and delivery methods for enhanced efficacy against HIV-1.

Keywords:

HIV-1 neutralizing antibodies antibody engineering antigen binding bispecific antibody gene delivery variable region

More Related Videos

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model

Published on: July 2, 2016

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Published on: June 23, 2011

Related Experiment Videos

Last Updated: Dec 21, 2025

Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies

Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies

Published on: August 29, 2017

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model

Published on: July 2, 2016

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Published on: June 23, 2011

Area of Science:

Immunology
Virology
Biotechnology

Background:

Broadly neutralizing human monoclonal antibodies (bNAbs) are a new class of antiretrovirals for HIV-1 treatment and prophylaxis.
While effective for passive protection, some bNAbs show limited efficacy in established HIV-1 infections.
Antibody engineering aims to enhance antiviral activity and overcome limitations of existing bNAbs.

Approach:

Reviewing antibody engineering technologies to create improved neutralizing antibodies against HIV-1.
Exploring rational antibody combinations and engineered antibodies (eAbs) as therapeutic candidates.
Discussing antibody delivery technologies, including viral and non-viral vectors, and stem cell-based approaches.

Key Points:

Engineering strategies include designing bispecific antibodies, modifying glycosylation, and structure-guided variable region alterations.
Fusion-neutralizing antibodies can enhance the activity and neutralizing spectrum of bNAb cocktails.
Advanced delivery systems are being investigated to optimize antibody efficacy.

Conclusions:

Engineered antibodies and novel delivery systems represent a promising therapeutic strategy against HIV-1.
Further research into optimized antibody combinations and delivery holds potential for improved HIV-1 treatment and prophylaxis.
Understanding mechanisms of action is crucial for developing next-generation antiretrovirals.